Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new revision entry (v3.5.4) was added to the page, replacing the previous revision (v3.5.3) in the study record’s history.
    Difference
    0.0%
    Check dated 2026-05-15T11:30:56.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s study page footer was updated to reflect a new site revision version (v3.5.3 instead of v3.5.2), with no visible change to the trial’s study details.
    Difference
    0.0%
    Check dated 2026-04-24T06:27:53.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Page revision tag updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:44:06.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T05:10:52.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing the previous Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T00:00:45.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.4.2' was added, and the previous banner about government funding and the older revision 'v3.4.1' were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:19:39.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.